

The effect of simvastatin treatment on TNF-alpha-induced inflammation in human vascular endothelial cells (HUVECs)

Büşra GÖRGÜN¹ , Betül İŞİNER KAYA^{2*} , Kübra KAYA¹ , Leyla Didem KOZACI^{1,3} 

¹Department of Translational Medicine, Institute of Health Sciences, Ankara Yıldırım Beyazıt University, Ankara, Turkey

²Department of Basic Sciences, Faculty of Dentistry, Burdur Mehmet Akif Ersoy University, Burdur, Turkey

³Department of Biochemistry, Faculty of Medicine, Ankara Yıldırım Beyazıt University, Ankara, Turkey

Received: 23.12.2022 • Accepted/Published Online: 16.04.2023 • Final Version: 13.06.2023

Abstract: This study investigates the effects of simvastatin (SMV) on human umbilical vein endothelial cells (HUVECs) inflamed by tumor necrosis factor-alpha (TNF-a). Cells were treated with simvastatin (5 µM, 10 µM, and 50 µM) with/without TNF (20 ng/mL). The effects of simvastatin on the proliferation of cells were examined, and its cytotoxic effect was determined by lactate dehydrogenase (LDH) assays. Metalloproteinase expression (MMP-2 and MMP-9) levels of SMV at different concentrations were determined by qPCR, and protein levels were determined by Western blot. The increasing concentrations of SMV down-regulated the expression levels of MMPs. After stimulation with TNF-a, the effect of SMV at different concentrations on wound healing time in case of wound formation was examined. The results interestingly indicated that SMV delayed the closure time 2.5-fold when it was administered alone to HUVECs but did not change the wound closure time in inflamed conditions. The study suggests that inflammation is a required condition in wound healing, and in the absence of inflammation, SMV treatment delays wound healing in vitro.

Key words: Human umbilical vein endothelial cell, simvastatin, tumor necrosis factor-alpha, matrix metalloproteinase, wound healing

1. Introduction

Homeostasis refers to the protection of stability against external disturbances, and in a more classical sense, it refers to maintaining the stability of systems. Cytokines control cell differentiation, survival, and death, which are essential for homeostasis. Tissue necrosis factor (TNF), a potent proinflammatory, is an important member of the cytokine family and can induce both inflammation and apoptotic cell death [1]. Regulation of cell growth and death is the main approach in the treatment of cancer and other proliferative diseases. In addition, TNF is involved in the pathogenesis of inflammatory diseases such as Crohn's disease, ulcerative colitis, rheumatoid arthritis, and insulin-resistant metabolic disorders [2-5]. Due to its role as a "master regulator" of TNF inflammatory cytokine production, it has been proposed as a therapeutic target for many diseases, and anti-TNF therapies have been investigated and widely used in clinical practice in recent years. Therefore, we used TNF-a as a stimulant in our study.

The human umbilical vein endothelial cells (HUVECs), known to be highly dynamic cells with a high degree of plasticity and differentiation potential, are

frequently encountered in studies investigating the effects of cytokines [6, 7].

Simvastatin (SMV) is in the group of statin drugs, developed to reduce cholesterol synthesis through the inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase. However, studies have been conducted showing that statins have pleiotropic effects independent of this inhibition [8,9]. Some of the studies have shown that statins have antiinflammatory properties and can reduce matrix metalloproteinase (MMP) expression and activity [10,11]. MMPs play important roles in physiological processes such as tissue regeneration and wound healing, in pathological conditions such as cardiovascular and neurological diseases, and in many important processes such as cell surface receptor division, the release of ligands, and cell proliferation. It has also been shown that the reduction in MMP secretion may be due to interference from statins in isoprenoid synthesis [12]. When MMPs are classified according to their substrate specificity, the gelatinases class includes MMP-2 and MMP-9 and has proinflammatory and antiinflammatory effects on many tissues [13]. However, the studies on this subject are very limited and the effect of SMV at different

* Correspondence: betulisiner@mehmetakif.edu.tr

concentrations has not been investigated in detail after inflammation of HUVEC with TNF- α .

The wound healing model, also known as scratch assay, is commonly used in studies investigating the effects of cytokines and has become popular in recent years and is a relatively new technique that can be used to investigate wound healing and cell migration *in vitro*. The technique reproduces the wound by creating a gap in the confluent cell layer. Homeostasis, inflammation, migration-proliferation, and maturation occur during wound healing. Under the influence of cytokines, keratinocytes behind the wound edge begin to proliferate and migrate to the wound bed. This process includes cell migration, proliferation, and differentiation [14]. The possible effects of simvastatin on this cell migration in cells stimulated by TNF, a well-known proinflammatory molecule, have not yet been investigated.

This study aimed to investigate the possible effect(s) of SMV on TNF- α treated HUVECs and their underlying mechanisms. In the study, HUVECs were stimulated using TNF (20 ng/mL) and treated with different concentrations of SMV (5, 10, and 50 μ M) to investigate the effect of MMP-2 and MMP-9 on mRNA and protein expression. Cell proliferation capacity was measured. Lactate dehydrogenase (LDH) activity was also monitored for toxicity assessment. In addition, a wound healing model was created. Using this model, the possible effects of different concentrations of simvastatin applied to TNF stimulated HUVECs on wound closure time were investigated.

2. Materials and methods

2.1. Materials

TNF- α was purchased from Biologend (San Diego, ABD). Simvastatin was purchased from Santa Cruz Biotechnology (Teksas, ABD). They are solubilized in ultra ddH₂O and dimethylsulfoxide (DMSO), respectively. Dulbecco's modified eagle medium (DMEM), and penicillin/streptomycin were obtained from Capricorn Scientific (Darmstadt, Germany). TRIzol reagent was obtained from Invitrogen (Cat No: 15596-026, MA, USA).

NG dART RT kit was purchased from EURx (Cat No: E0801-02, Gdańsk, Polonia). BrightGreen 2X qPCR MasterMix-No Dye kit was from Applied Biological Materials Inc. Abm (Cat No: MasterMix-S, Richmond, Canada), cytotoxicity detection kit was purchased from Roche (Munich, Germany).

PVDF membranes were obtained from Merck Millipore (cat no. IPVH00010, CA, USA). MMP-2 and MMP-9 were purchased from St John's Laboratories (dilution, PBS-T, 1:1000, cat. no. STJ94163 and STJ93257, respectively). Beta-actin was obtained from Elabscience (dilution, PBS-T, 1:3000, cat. no. E-AB-00156, Houston,

USA). Goat anti-rabbit IgG H&L (HRP) was obtained from Abcam (ab97051; Abcam). PBS tablet (Merck Millipore, Darmstadt, Germany), Tween 20 was purchased from Sigma-Aldrich (Cat no: P1379, St. Louise, USA).

2.2. Cell line and cell culture

The study was conducted in accordance with the guidelines of the Institutional Ethics Committee. A commercially available human umbilical vein endothelial cell line (HUVEC) was used. Cells were cultured at 37 °C in a humidified atmosphere of 5% CO₂ in DMEM without FBS, containing 1% L-Glutamine (4.0 mM) and 1% penicillin-streptomycin, and glucose (4.5 g/L).

$3 \times 10^5/2000$ μ L cells were seeded into each well of 6-well sterile plates and cultured in an incubator for 24 h to adhere to the base and grow. Cells, whose medium was changed after washing with PBS twice, were monitored taking into account the scheduled times for the study (24 h for qPCR, 48 h for wound assay using Zencell System).

Cells were divided into groups: culture medium without any treatment as a control group; culture medium containing TNF- α (20 ng/mL) as positive control; culture medium containing only simvastatin (50 μ M); culture medium containing TNF- α (20 ng/mL) with different doses of simvastatin (5, 10, and 50 μ M) as the treatment group, respectively (Table 1).

These concentrations of simvastatin were chosen by reviewing articles as they were close to the concentration detected in the human body when administered therapeutically.

Following TNF- α stimulation, the effects of simvastatin treatment on cells were monitored at 12, 24, and 48 h. Total cell number, number of cells adhered to the plate, and number of cells detached from the plate were calculated as fold change compared to control group. Experiments were performed in duplicate for each condition.

2.3. Cytotoxicity analysis with LDH

Lactate dehydrogenase (LDH) activity was measured for toxicity assessment in cell culture. At the 24th hour after all treatments, 100 μ L of the media in which the cells were contained were collected and Roche cytotoxicity detection kit was used to determine the LDH activity. The absorbance values obtained by the spectrophotometric method at 492 nm were recorded. Protein content was determined using a Pierce™ BCA Protein Assay kit (cat. no. 23225, Thermo Fisher Scientific, Inc.).

2.4. Polymerase chain reaction (PCR) analysis

0.5 mL of TRIzol reagent was added per well and the lysate was formed by mixing the cells at room temperature for 5 min. Lysates were taken into RNAase/DNAase-free Eppendorf tubes (1.5 mL). These tubes were centrifuged at 12,000 g, 4 °C for 10 min to collect supernatants and cellular RNA was isolated from the supernatant according to the kit instructions.

qPCR was used to analyze mRNA expressions (MMP-2, MMP-9). cDNA was also synthesized using the NG dART RT kit. The primer pairs (forward and reverse) used for MMP-2, MMP-9, and GAPDH are listed in Table 2.

The reactions were performed using a qPCR analyzer (Rotor-Gene Q, Qiagen, Germany) under the conditions of 10 min at 95 °C (1 cycle); 15 s at 95 °C; 60 s (40 cycles) at 60 °C. GAPDH values were used as an internal control to normalize expression data.

2.5. Western blotting

Proteins were extracted from HUVEC using Laemmle buffer containing proteinase inhibitor. The total protein amount was calculated using the Pierce™ BCA Protein Assay kit procedure. The samples (15 µg) were transferred to the PVDF membrane (0.45 µm) with a semidry transfer device (BIO-RAD) after electrophoresis in the prepared 10% polyacrylamide gel.

PBS-T containing 0.1% Tween 20 and 3% skimmed milk powder was applied for 1 h to reduce nonspecific binding to the membrane. The membranes were incubated on a shaker at 4 °C for 16 h by adding primary antibodies to MMP-2, MMP-9, and Beta-actin. After the incubation period was completed, the membranes were washed 3

times with 1X PBS-T solution for 5 min and incubated for 1 h with the secondary antibody Goat pAb to Rb IgG. Membranes were washed again with 1X PBS-T solution 3 times for 5 min. ECL solution was added to the membranes to see the protein bands and after 2 min in the dark, imaging was performed with the ChemiDoc ItR2 Imager (UVP) device. Bands were analyzed with the Image J program.

2.6. Wound healing assay

The HUVEC cell line was cultured at 10,000 cells/well/500 µL in a 24-well cell culture plate. After 4 days, a wound model was created by mechanical scratching using a 100-µL sterile tip. Next, the treatments shown in Table 1 were applied to examine the effects of TNF and simvastatin on HUVECs in wound healing model (Table 1). At this stage, a fresh medium (high glucose DMEM) containing 5% FBS was used. Cells were incubated for 48 h in the incubator and imaged using a 24-channel ZenCell Owl (Live Cell Imaging, InnoME GmbH, Bremen, Germany) device that allows real-time microscopic images of wound closure. The wound healing times (hours) were measured according to the migration of cells to fill the injured area is the first step in the wound healing process according to

Table 1. Treatment groups of the study.

Groups	Treatment applications
1	Control*
2	TNF-a
3	SMV (50 µM)
4	TNF-a + SMV (5 µM)
5	TNF-a + SMV (10 µM)
6	TNF-a + SMV (50 µM)

*Control group includes only HUVEC
(Abbreviations: TNF-a, Tumor necrosis factor-alpha; SMV, simvastatin)

Table 2. Primer sequences.

Primer name	Primer sequence
MMP-2 human forward	TGACGGTAAGGACGGACTC
MMP-2 human reverse	ATACTTCACACGGACCACTTG
MMP-9 human forward	CTGGGCAGATTCCAAACCT
MMP-9 human reverse	TACACGCGAGTGAAGGTGAG
GAPDH human forward	TGATGACATCAAGAAGGTGGTGAAG
GAPDH human reverse	TCCTTGGAGGCCATGTGGGCCAT

(Abbreviations: GAPDH, glyceraldehyde 3-phosphate dehydrogenase; MMP, matrix metallo proteinase; G, guanine; C, cytosine; A, adenine; T, thymine)

our measurement procedure, we recorded the hour the cells first interacted in the plot gap area.

2.7. Statistical analysis

Each experiment was repeated two times. Results were given as mean ± standard deviation (SD) or mean ± standard error of the mean (SEM) and analyzed by ANOVA using Tukey correction for multiple comparisons. Statistical analysis was performed with the SPSS computer program v. 20.0, IBM corp., USA). p < 0.05 was considered statistically significant.

3. Results


3.1. Cell proliferation

Immunocytochemical analyses of HUVECs were performed. It was determined that these cells were induced

by TNF, and then, as a result of combined treatment with SMV at different concentrations, the total number of cells, and cell numbers adhered to and detached from the plate surface were calculated (Figure 1). SMV treatment and TNF-a stimulation affected HUVEC proliferation in a dose- and time-dependent manner in 48-h cultures.

The total cell number increased continuously in all groups (except only SMV used) within 48 hours. However, high concentrations of SMV (50 µM) treatment in TNF-induced HUVECs significantly increased the cell number.

In the group using the highest concentration of SMV (TNF-a + SMV 50 µM), the number of cells adhering to the base of the plate did not change much over time. The number of these cells increased over time in groups using medium (TNF-a + SMV 10 µM) and low concentration






Figure 1. HUVECs proliferation has been stimulated with 20 ng/mL TNF-a and treatment with different concentrations of simvastatin for 12, 24, and 48 h. The graphics show the fold increase of the total cells (a), the cells adhered to the plaque surface (b), and the cells detached from the plaque surface (c). Experiments were carried out in duplicate for each condition. Bars represent the standard error of the mean. $p < 0.05$ was calculated for groups a,b,c vs control group ($p = 0.048$; 0.027 ; 0.003 , respectively). *Statistically significant compared to the control ($p < 0.05$). #Groups are control, TNF-a, SMV (50 μ M), TNF-a + SMV (5 μ M), TNF-a + SMV (10 μ M), TNF-a + SMV (50 μ M), respectively.

(TNF-a + SMV 5 μ M). However, compared to the control group, SMV and TNF-a applied to HUVECs, especially TNF-a alone, decreased the number of cells adhering to the plate surface in all groups.

However, increasing the concentration of SMV treatment significantly increased the number of cells detached from the plate surface in TNF-induced HUVECs. In the group treated with high concentrations of simvastatin (TNF-a + SMV 50 μ M), the number of cells detached from plate surface increased over the 24-h periods but not afterward.

3.2. Cytotoxic effects of simvastatin after inflammation of HUVECs with TNF-a

Toxicity assessment in cell culture was performed using an assay based on the measurement of lactate dehydrogenase (LDH) activity. The six groups (control and treatment groups) were compared to LDH activity in HUVECs (Figure 2). To determine the LDH activity in the media, the toxicity of the treatments was evaluated with the absorbance data obtained by the spectrophotometric method at 492 nm.

TNF- α inflammation of HUVECs significantly decreased cytotoxicity. While SMV treatment alone increased this cytotoxic effect, increased concentration of SMV treatment in TNF- α -stimulated HUVECs decreased the cytotoxic effect.

3.3. Effects of simvastatin on mRNA expression of MMP-2 and MMP-9 after inflammation of HUVECs with TNF-a

The mRNA expression levels of MMPs were evaluated. Changes in MMP expressions observed in treatment

groups were compared with gene expression in the control group and calculated relative to the control group (Figure 3).

mRNA expression in HUVECs increased approximately 2-fold (MMP-9) and 20-fold (MMP-2) in TNF-induced cells after SMV treatment compared to the control group. While the effect of SMV on the release of the MMP-9 form in these stimulated cells was more modest, its effect on MMP-2 was found to be much greater.

When the effects of SMV concentrations (5, 10, and 50 μ M) were examined, mRNA expression of MMP-2 and -9 genes were down-regulated gradually in a dose-dependent manner. According to the results obtained, it was determined that the 5- μ M dose was the most effective dose for MMP-2 and -9. In addition, only SMV treatment quite up-regulated the mRNA expression of MMP-2 ($p < 0.05$).

3.4. Western blot

MMP-2 and -9 protein expressions were measured in HUVEC lysates by western blot analysis and the results are given in Figure 4.

Protein levels of MMP-2 and -9 were increased with TNF combined SMV treatment in HUVECSs compared with the control group. While an increase was observed in the protein levels of MMP-2 with the increase of SMV concentration; MMP-9 protein levels first decreased and then a slight increase was observed. However, the greatest difference was experienced in the TNF stimulated HUVEC group, which received the highest dose of SMV.




Figure 2. The effect of SMV treatment on LDH activity present in culture medium in TNF-a stimulated HUVEC cultures. Data are presented as fold change of LDH levels compared to the controls. All experiments were performed in duplicate. Error bars represent SD. *Statistically significant compared to the control ($p < 0.05$).




Figure 3. Effect of SMV on MMP-2 and MMP-9 mRNA expression levels: **a.** MMP-2 and **b.** MMP-9 production by TNF induced cells after treatment for 48 h. The data was taken from two separate experiments, each performed in duplicate. Error bars represent SD. Statistically significant compared to the groups for MMP-2 ($p = 0.033$; $p < 0.05$). *Statistically significant compared to the control ($p < 0.05$).




Figure 4. Effect of SMV on MMP-2 and MMP-9 protein expression. a. MMP-2 and b. MMP-9 protein release after SMV treatment on TNF-a induced HUVECs. The data was taken from two separate experiments, each performed in duplicate. Error bars represent SD. Statistically significant compared to the groups for MMP-2 ($p = 0.009$; $p < 0.05$). *Statistically significant compared to the control ($p < 0.05$).

3.5. Wound healing assay

The HUVEC cell line was cultured in a 24-well cell culture plate and 4 days later, using a 100- μ L sterile tip, a wound healing model was generated and wound healing times were measured (hours).

The results obtained when different concentrations of simvastatin were monitored on wound healing of TNF-stimulated HUVEC cells are given in Figure 5. While a wound healing time of 35 h was found in cells treated with only SMV, simvastatin concentration did not make a difference in cells with inflammation with TNF.

Images of the cells were taken hourly using the ZenCellOwl device for 48 h after SMV treatment at different concentrations applied to the cells stimulated with TNF- α . The wound healing images of HUVECs were given in Figure 6 at the hour of 0, at the wound healing time, and at 5-h posthealing.

4. Discussion

This study aimed to investigate the effects of SMV at different concentrations on HUVECs induced with TNF. Our study includes cell proliferation, possible cytotoxic effects, possible effects on mRNA and protein expression and wound healing times were investigated. All these studies were performed in the case of SMV treatment, in the case of TNF stimulation, and in the conditions of SMV treatment at different concentrations after stimulation with TNF.

In the study, the effects of TNF- α and SMV on the proliferation of HUVECs and the attachment of cells to plates were investigated. It was observed that the total cell number decreased when only SMV was applied to HUVECs, but the cell number increased proportionally when SMV was applied to TNF-stimulated cells. The most significant decrease in the number of plate-bound cells was observed only when HUVECs were stimulated with TNF. The number of cells detached from the plate increased significantly with increasing SMV concentration in TNF

stimulated HUVECs. Increasing the concentration of SMV treatment decreased the surface-attachment properties of TNF- α -stimulated HUVECs. Studies showing that SMV induces p21- and p27-dependent G0/G1 cell cycle arrest in cell lines support our findings [7,15]. It has been shown that one of the reasons for the deterioration in this proliferation is SMV via vascular endothelial growth factor (VEGF) and it reduces dose-dependent proliferation [16]. In support of this, clinical studies have found a correlation between blood VEGF concentration and statin therapy [17].

LDH level was also discussed in our study as it is an indicator of cytotoxicity and cell death, and it was seen that the highest cell death was only with SMV application to HUVECs. Statins, of which SMV is an important member, have mechanisms of action such as inhibition of cell proliferation, cell cycle arrest, induction of apoptotic cell death, and inhibition of metastasis [18, 19]. The underlying mechanism of these effects is the inhibition of AMPK activation caused by statins, some protein synthesis, and suppression of cell proliferation [20,21]. It is also an expected result that the LDH level, that is, cytotoxicity, is low in cells stimulated with only TNF- α . In our study, we see that cell death is reduced again when we look at the effects of SMV application at different concentrations on HUVECs stimulated by TNF- α on the LDH level. In contrast to SMV, TNF- α is known to significantly




Figure 5. The graph presents durations of closure time of the created clefts by HUVECs treated with/without TNF- α and different concentrations of SMV. For the migration characteristics of the cells, a slit pattern was established when the cells completely covered the well surface. The closure time of this created cleft was recorded using ZenCellOwl device for 48 h, real-time images of the cells were monitored with 1-h cycles with a ZenCellOwl microscope, and then the closing times were determined.

*Groups are 1. control, 2. TNF- α , 3. SMV (50 μ M), 4. TNF- α + SMV (5 μ M), 5. TNF- α + SMV (10 μ M), 6. TNF- α + SMV (50 μ M).




Figure 6. Images of the wound healing of HUVECs. A wound scratch assay was performed using ZenCell. Images were given at the start of the wound formation (0 h) and wound healing time.*Groups are 1. control, 2. TNF-a, 3. SMV (50 μ M), 4. TNF-a + SMV (5 μ M), 5. TNF-a + SMV (10 μ M), 6. TNF-a + SMV (50 μ M).

stimulate HUVEC proliferation at concentrations above 1 ng/mL [22]. On the contrary, a study also found that TNF- α can induce HUVEC apoptosis and inhibit HUVEC proliferation [23].

MMPs play an important role in physiological and pathological states involving inflammation, and inflammatory-related functions, including the activity of cytokines [24]. Therefore, in the study's next step, the effect of SMV treatment after TNF stimulation on MMP-2 and MMP-9 expression and protein expression in HUVECs was examined. Study results showed that SMV treatment administered to HUVECs after TNF stimulation down-regulated genes in both MMP-2 and 9 in HUVECs in a dose-dependent manner as the concentration increased. This decrease may be responsible for increased number of cells detached from the plate surface. However, although we observed a decrease in MMP-9 levels, the differences between the groups were not statistically significant. Cytokines, including TNF, are known to be induced by MMPs and induce inflammation [25]. Expression of MMPs in different cell types has also been shown to be induced by an extracellular stimulus such as TNF. The mechanism underlying the regulation of TNF and MMP expression is related to c-Src, MAPK, and NF- κ B in metabolic pathways [26]. Statins, on the other hand, have antiinflammatory effects and down-regulate the expression of MMPs. Lipophilic statins such as simvastatin more than hydrophilic statins such as pravastatin were found to down-regulate MMP-9 activity, which is consistent with our study results. Another study, including some of the authors, found that SMV also down-regulated the MMP-2 and MMP-9 genes in the interleukin 1 β -induced SW1353 chondrosarcoma cell line [27]. In another study in which they looked at the possible effects of 1.25(OH) $_2$ D $_3$ in human chondrocyte and SW1353 cells stimulated with TNF- α , MMP-1, -2, -3, -9, and -13 mRNA expressions were again decreased with 1.25(OH) $_2$ D $_3$ treatment [28]. In our study, we can say that increasing the concentration of SMV treatment reversed the effects of MMP-2 and MMP-9 on mRNA expression levels in TNF stimulated HUVECs. These results are very significant to offer new strategies for intervention with inflammatory diseases without blocking the beneficial effects of MMPs.

Bernds' study found that SMV increased the proteolytic capacity of MMP-2 and MMP-9 [29]. Our study observed a similar situation in the MMP-2 level with SMV administration in cells stimulated with TNF- α . A small decrease in MMP-9 followed by an increase in protein expression was observed in the same way. Because of the increased expression and activity of these MMPs in tumors, each factor affecting this expression is critical. Therefore, the results of this study show that SMV treatment can suppress tumor progression and invasion by down-regulating specifically MMP-9 levels in TNF-

stimulated HUVECs. These findings may also contribute to developing new preventive treatments for different diseases.

Wound healing researches are useful tools to develop therapies to heal wounds in a shorter period, avoiding negative consequences such as infection and scarring. In our study, we conducted a time study on wound healing by creating a wound model to determine the dose-dependent potency of SMV on cell motility. According to the results of our research, wound closure time increased 2.5 times in cells treated with only SMV. However, it was observed that SMV concentration did not affect the closure time in HUVECs stimulated with TNF- α .

Wound healing is a dynamic and complex process involving coordinated events such as proliferation, hemostasis, inflammation, and revascularization [30]. Statins have been recognized as a new therapeutic modality for wound healing due to their various pleiotropic potency, independent of their lipid-lowering effects [31]. It has been suggested that these broad-spectrum pleiotropic effects of statins are related to their antiinflammatory, antioxidant, and immunomodulatory properties and ability to improve reperfusion [32-35]. The possible effects of statins on wound healing have not yet been adequately studied. The prognostic effects of statins in the wound healing process are rational and the results are promising. However, our study observed that high statin administration doses created a negative result interestingly and prolonged wound closure time. Interestingly, however, administration of simvastatin after inflammation reduced the wound healing time of simvastatin. Similar to our study, some studies found that SMV delays wound healing by inhibiting VEGF protein secretion and disrupting proliferation. SMV, along with many statin types showing significant antiproliferative and antimigratory properties, inhibits isoprenylation and cell growth factor (HGF)-dependent cell migration [7]. On the other hand, several other studies have shown that statins aid wound healing by increasing endothelial formation by inducing NO synthase, increasing VEGF release, and reducing oxidative stress [36-39]. Considering the different pleiotropic and prognostic effects of SMV in the wound healing process, it should be taken into account that the possible effect of SMV on wounds in different tissue types may also differ.

5. Conclusion

This study suggests that SMV treatment, with/without TNF stimulation, affects cell proliferation, MMP mRNA and protein expression and wound healing in HUVECs differentially. That research should be applied by simulating various pathological processes to fully comprehend statins' acting mechanisms.

Conflict of interest

The authors declare no conflicts of interest.

References

1. Yang G, Shao GF. Elevated serum IL-11, TNF alpha, and VEGF expressions contribute to the pathophysiology of hypertensive intracerebral hemorrhage (HICH). *Neurological Sciences* 2016; 37: 1253-1259. <https://doi.org/10.1007/s10072-016-2576-z>
2. Podolsky DK. Inflammatory bowel disease. *The New England Journal of Medicine: Research & Review* 2002; 347: 417-429. <https://doi.org/10.1056/NEJMra020831>
3. Lin J, Ziring D, Desai S, Kim S, Wong M et al. TNF α blockade in human diseases: An overview of efficacy and safety. *Clinical Immunology* 2008;126: 13-30. <https://doi.org/10.1016/j.clim.2007.08.012>
4. Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. *Current Directions in Autoimmunity* 2010; 11: 180-210. <https://doi.org/10.1159/000289205>
5. Page MJ, Bester J, Pretorius E. The inflammatory effects of TNF- α and complement component 3 on coagulation. *Scientific Reports* 2018; 8: 1812-1821. <https://doi.org/10.1038/s41598-018-20220-8>
6. Aguilar-Va'zquez R, Carballo-Molina OA, Collazo-Navarrete O, Guerrero-Rangel M, Saucedo-Campos AD et al. Osteogenesis of human vascular endothelial cells in culture. *Revista de Investigación Clínica* 2008; 60 (6): 496-501.
7. Burgazli KM, Bui KL, Mericliiler M, Albayrak AT, Parahuleva M et al. The effects of different types of statins on proliferation and migration of HGF-induced Human Umbilical Vein Endothelial Cells (HUVECs). *European Review for Medical and Pharmacological Sciences* 2013; 17: 2874-2883.
8. Liao JK, Laufs U. Pleiotropic effects of statins. *Annual Review of Pharmacology and Toxicology* 2005; 45:89-118. <https://doi.org/10.1146/annurev.pharmtox.45.120403.095748>
9. Souza-Costa DC, Sandrim VC, Lopes LF, Gerlach RF, Rego EM et al. Anti-inflammatory effects of atorvastatin: modulation by the t-786c polymorphism in the endothelial nitric oxide synthase gene. *Atherosclerosis* 2007b; 193 (2): 438-444. <https://doi.org/10.1016/j.atherosclerosis.2006.07.020>
10. Kamio K, Liu XD, Sugiura H, Togo S, Kawasaki S et al. Statins inhibit matrix metalloproteinase release from human lung fibroblasts. *European Respiratory Society* 2010; 35 (3): 637-646. <https://doi.org/10.1183/09031936.00134707>
11. Massaro M, Zampolli A, Scoditti E, Carluccio MA, Storelli C et al. Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: antiangiogenic actions possibly contributing to plate stability. *Cardiovasc Research* 2010; 86 (2): 311-320. <https://doi.org/10.1093/cvr/cvp375>
12. Lopez-Otin C, Hunter T. The regulatory crosstalk between kinases and proteases in cancer. *Nature Reviews. Cancer* 2010; 10 (4): 278-292. <https://doi.org/10.1038/nrc2823>
13. Provenzano M, Andreucci M, Garofalo C, Faga T, Michael A et al. The association of matrix metalloproteinases with chronic kidney disease and peripheral vascular disease: a light at the end of the tunnel? *Biomolecules* 2020; 10 (1): 154-170. <https://doi.org/10.3390/biom10010154>
14. Grada A, Otero-Vinas M, Prieto-Castrillo F, Obagi Z, Falanga V. Research techniques made simple: analysis of collective cell migration using the wound healing assay. *Journal of Investigative Dermatology* 2017; 137(2): 11-16. <https://doi.org/10.1016/j.jid.2016.11.020>
15. Wang S, Ho HJ, Lin J, Shieh J, Wu C. Simvastatin-induced cell cycle arrest through inhibition of STAT3/SKP2 axis and activation of AMPK to promote p27 and p21 accumulation in hepatocellular carcinoma cells. *Cell Death & Disease* 2017; 8 (2): 2626-2638. <https://doi.org/10.1038/cddis.2016.472>
16. Hata Y, Miura M, Asato R, Kita T, Oba K et al. Antiangiogenic mechanisms of simvastatin in retinal endothelial cells. *Graefes' Archive for Clinical and Experimental Ophthalmology* 2010; 248: 667-673. <https://doi.org/10.1007/s00417-009-1282-4>
17. Trapé J, Morales C, Molina R, Filella X, Marcos Jm et al. Vascular endothelial growth factor serum concentrations in hypercholesterolemic patients. *Scandinavian Journal of Clinical and Laboratory Investigation* 2006; 66: 261-267. <https://doi.org/10.1080/00365510600564949>
18. Roy M, Kung HJ, Ghosh PM. Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-binding proteins. *American Journal of Cancer Research* 2011; 1: 542-561.
19. Lonardo A, Loria P. Potential for statins in the chemoprevention and management of hepatocellular carcinoma. *Journal of Gastroenterology and Hepatology* 2012; 27: 1654-1664. <https://doi.org/10.1111/j.1440-1746.2012.07232.x>
20. Motoshima H, Goldstein BJ, Igata M, Araki E. AMPK and cell proliferation—AMPK as a therapeutic target for atherosclerosis and cancer. *The Journal of Physiology* 2006; 574: 63-71. <https://doi.org/10.1113/jphysiol.2006.108324>
21. Sala SG, Munoz U, Bartolome F, Bermejo F, Martin-Requero A. HMG-CoA reductase inhibitor simvastatin inhibits cell cycle progression at the G1/S checkpoint in immortalized lymphocytes from Alzheimer's disease patients independently of cholesterol-lowering effects. *Journal of Pharmacology and Experimental Therapeutics* 2008; 324: 352-359. <https://doi.org/10.1124/jpet.107.128959>
22. Zhang B, Ouyang P, Chen Y, Lai W, Xie J et al. Tumor necrosis factor- α regulates the proliferation and syndecan-4 expression of human umbilical vein endothelial-like cells cultured in vitro. *Nan Fang Yi Ke Da Xue Xue Bao* 2007; 27 (4): 496-508.
23. Jiang C, Fang X, Jiang Y, Shen F, Hu Z et al. TNF- α induces vascular endothelial cells apoptosis through overexpressing pregnancy induced noncoding RNA in Kawasaki disease model. *The International Journal of Biochemistry & Cell Biology* 2016; 72: 118-124. <https://doi.org/10.1016/j.biocel.2016.01.011>

24. Nissinen L, Kähäri V. Matrix metalloproteinases in inflammation. *Biochimica et Biophysica Acta* 2014; 1840 (8): 2571-2580. <https://doi.org/10.1016/j.bbagen.2014.03.007>
25. Lee WJ, Shin CY, Yoo BK, Ryu JR, Choi EY et al. Induction of matrix metalloproteinase-9 (MMP-9) in lipopolysaccharide-stimulated primary astrocytes is mediated by extracellular signal-regulated protein kinase 1/2 (Erk1/2). *Glia* 2003; 41: 15-24. <https://doi.org/10.1002/glia.10131>
26. Eberhardt W, Huwiler A, Beck KF, Walpen S, Pfeilschifter J. Amplification of IL-1 beta-induced matrix metalloproteinase-9 expression by superoxide in rat glomerular mesangial cells is mediated by increased activities of NF-kappa B and activating protein-1 and involves activation of the mitogen-activated protein kinase pathways. *Journal of Immunology* 2000; 165: 5788-5797. <https://doi.org/10.4049/jimmunol.165.10.5788>
27. Cecen B, Keles D, Oktay G, Kozaci LD. Effects of simvastatin on matrix metalloproteinase regulation in IL-1 β -induced SW1353 cells. *Chemico-Biological Interactions* 2019; 310: 108730-108736. <https://doi.org/10.1016/j.cbi.2019.108730>
28. Avcioglu G, Özbekİpteç B, Akcan G, Görgün B, Fidan K et al. Effects of 1.25-Dihydroxy vitamin D3 on TNF- α induced inflammation in human chondrocytes and SW1353 cells: a possible role for toll-like receptors. *Molecular and Cellular Biochemistry* 2020; 464 (1-2): 131-142. <https://doi.org/10.1007/s11010-019-03655-z>
29. Bernd C, Kieseier MD, Juan J, Archelos MD, Hans-Peter Hartung MD. Different Effects of Simvastatin and Interferon Beta on the Proteolytic Activity of Matrix Metalloproteinases. *Archives of Neurology* 2004; 61 (6): 929-932. <https://doi.org/10.1001/archneur.61.6.929>
30. Vukelic S, Stojadinovic O, Pastar I, Vouthounis C, Krzyzanowska A et al. Farnesyl pyrophosphate inhibits epithelialization and wound healing through the glucocorticoid receptor. *Journal of Biological Chemistry* 2010; 285 (3): 1980-1988. <https://doi.org/10.1074/jbc.M109.016741>
31. Libby P OY, Rocha VZ, Folco E. Inflammation in atherosclerosis: transition from theory to practice. *Circulation Journal* 2010; 74 (2): 213-220. <https://doi.org/10.1253/circj.cj-09-0706>
32. Diomedea L, Albani D, Sottocorno M, Donati MB, Bianchi M et al. In vivo antiinflammatory effect of statins is mediated by nonsterol mevalonate products. *Arteriosclerosis, thrombosis, and vascular biology*. 2001; 21 (8): 1327-1332. <https://doi.org/10.1161/hq0801.094222>
33. Mach F. Statins as immunomodulatory agents. *Circulation*. 2004; 109 (21): 15-17. <https://doi.org/10.1161/01.CIR.0000129502.10459.fe>
34. Adam O, Laufs U. Antioxidative effects of statins. *Archives of toxicology* 2008; 82 (12): 885-92. <https://doi.org/10.1007/s00204-008-0344-4>
35. Jerwood S, Cohen J. Unexpected antimicrobial effect of statins. *Journal of antimicrobial chemotherapy*. 2008; 61 (2): 362-364. <https://doi.org/10.1093/jac/dkm496>
36. Rego ACM, Ara'ujo Filho I, Damasceno BPGL, Egitto EST, Silveira IA et al. Simvastatin improves the healing of infected skin wounds of rats. *Acta Cirúrgica Brasileira* 2007; 22 (1): 57-63. <https://doi.org/10.1590/s0102-86502007000700012>
37. Bitto A, Minutoli L, Altavilla D, Polito F, Fiumara T et al. Simvastatin enhances VEGF production and ameliorates impaired wound healing in experimental diabetes. *Pharmacological Research* 2008; 57 (2): 159-69. <https://doi.org/10.1016/j.phrs.2008.01.005>
38. Holler V, Buard V, Gaugler MH, Guipaud O, Baudelin C et al. Pravastatin limits radiation-induced vascular dysfunction in the skin. *Journal of Investigative Dermatology* 2009; 129 (5): 1280-1291. <https://doi.org/10.1038/jid.2008.360>
39. Laing T, Hanson R, Chan F, Bouchier-Hayes D. Effect of pravastatin on experimental diabetic wound healing. *Journal of Surgical Research* 2010; 161 (2): 336-40. <https://doi.org/10.1016/j.jss.2009.01.024>